Find a Provider

Henry T. Tsai, MD

There are 24 Clinical Trials currently being conducted by Henry T. Tsai, MD

Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors

Cancer

Closed

A022102: mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

Cancer

Open

Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer

Cancer

Open

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection.A212102: Multicancer Early Detection (MCED)

Cancer

Open

Observational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström Macroglobulinemia

Cancer

Open

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

Cancer

Open

CompassHER2-T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial

Cancer

Closed

Monitoring Symptoms to Help Young Women Take Hormone Therapy for Stage I-III Breast Cancer, ASPEN Study

Cancer

Closed

S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer

Cancer

Closed

A032101: Testing Interruption of Hormonal Medications in Patients Responding Exceptionally to Therapy for Metastatic Prostate Cancer, (A-DREAM)

Cancer

Closed

S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery

Cancer

Closed

Study of Personalized Cancer Therapy to Determine Response and Toxicity. UCSD-HRPP-130794

Cancer

Open

Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

Cancer

Closed

Breast Cancer WEight Loss Study (BWEL Study)

Cancer

Closed

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

Cancer

Open

Testing Low Dose Tamoxifen for Invasive Breast Cancer, the (LoTam) Trial

Cancer

Open

A Randomized Phase II/III Study of Docetaxel and Ramucirumab With or Without Cemiplimab for Participants Previously Treated With Platinum-Based Chemotherapy and Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)

Cancer

Open

Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study

Cancer

Open

NRG-GI008 Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US)

Cancer

Open

S2209-A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail or in a Subset of "Intermediate Fit" Comparing Upfront Three-Drug Induction Regimens Followed by Double or Single-Agent Maintenance

Cancer

Open

Docetaxel Addition in Metastatic Castrate-Sensitive Prostate Cancer (ASPIRE)

Cancer

Open

Cancer

Open

A012303 ShortStop-HER2: Shortened Duration of Adjuvant Therapy in Patients with Early-Stage HER2+ Breast Cancer Who Achieve pCR After Neoadjuvant Chemotherapy with HER2 Blockade

Cancer

Open

S2212 (SCARLET):Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer

Cancer

Open

Henry Tsai, MD

LIVE